Table 1.
Demographic and Clinical Characteristics of 10741 COVID-19-Positive Inpatients
| Ondansetron Group 0 (No Ondansetron; n = 9540) | Ondansetron Group 1 (<8 mg in First 24 h; n = 750) | Ondansetron Group 2 (≥8 mg in First 24 h; n = 451) | All Patients (n = 10 741) | |
|---|---|---|---|---|
| Male sex, No. (%) | 9125 (95.6) | 675 (90.0) | 388 (86.0) | 10 188 (94.9) |
| Median age (IQR), y | 72 (63–78) | 66 (55–73) | 63 (49–72) | 71 (62–77) |
| Age group 1 (≤49), No. (%) | 708 (7.4) | 127 (16.9) | 117 (25.9) | 952 (8.9) |
| Age group 2 (50–59), No. (%) | 963 (10.1) | 121 (16.1) | 78 (17.3) | 1162 (10.8) |
| Age group 3 (60–69), No. (%) | 2193 (23.0) | 204 (27.2) | 102 (22.6) | 2499 (23.3) |
| Age group 4 (≥70), No. (%) | 5676 (59.5) | 298 (39.7) | 154 (34.1) | 6128 (57.1) |
| White, non-Hispanic (%) | 4694 (49.2) | 385 (51.3) | 231 (51.2) | 5310 (49.4) |
| Black or African American (%) | 3179 (33.3) | 222 (29.6) | 132 (29.3) | 3533 (32.9) |
| Hispanic or Latino (%) | 773 (8.1) | 71 (9.5) | 40 (8.9) | 884 (8.2) |
| Other race (%) | 167 (1.6) | 21 (2.8) | 15 (2.7) | 203 (1.8) |
| Unknown race (%) | 664 (7.0) | 41 (5.5) | 30 (6.7) | 735 (6.8) |
| Previously healthy, No. (%) | 1223 (12.8) | 126 (16.8) | 94 (20.8) | 1443 (13.4) |
| At least 1 underlying condition, including obesity, No. (%) | 8317 (87.2) | 624 (83.2) | 357 (78.8) | 9298 (86.6) |
| Respiratory, No. (%) | 3325 (34.9) | 237 (31.6) | 105 (23.2) | 3667 (34.1) |
| Hypertension, No. (%) | 7476 (78.4) | 557 (74.3) | 308 (68.0) | 8341 (77.7) |
| Diabetes, No. (%) | 4882 (48.8) | 341 (54.5) | 211 (53.0) | 5210 (48.5) |
| Obesity, No. (%) | 3300 (34.6) | 304 (40.5) | 163 (36.1) | 3167 (29.5) |
| Average length of stay excluding patients who died at discharge ± SD, d | 11.60 ± 12.90 | 10.01 ± 11.10 | 9.22 ± 9.28 | 11.38 ± 12.65 |
| Median length of stay excluding patients who died at discharge ± SD, d (P value relative to group 0) | 6.86 ± 13.66 | 6.01 ± 11.76 (P = .0034**) | 6.50 ± 9.55 (P < .001***) | 6.81 ± 13.39 |
Numbers of patients and percentages from each of the above demographics and clinical comorbidities for each of the ondansetron groups are shown. In addition, the average and median lengths of stay are shown.
Abbreviation: COVID-19, coronavirus disease 2019.
*P < .05; **P < .01; ***P < .001.